Mitsubishi Tanabe Pharma America logo

Edaravone and Clinical Trials

Review information on clinical trials that mention the use of edaravone within their protocols.

Information on this website is available for US healthcare providers (HCPs) only.

Click here to confirm that you are a US HCP.
ENTER
Clipboard icon

Edaravone and Clinical Trialsa

Some current ALS clinical trials may mention the use of edaravone as part of their inclusion criteria. Additional information is available below. Please refer to each sponsor for complete and current information about each clinical trial, including protocols and inclusion/exclusion criteria.

According to ClinicalTrials.gov, the following clinical trials mention edaravone use in the inclusion criteria:

BIIB067 - VALOR (Part C) (Biogen)

—Edaravone study participants must have initiated edaravone ≥60 days (2 treatment cycles) prior to Day 1 and are expected to remain at that dose until the final study visit. If the Investigator determines that edaravone should be discontinued for medical reasons, it may not be restarted during the study. Edaravone may not be administered on dosing days of this study

See reference

Healey ALS Platform Trial:

  • CNM-Au8 (Clene Nanomedicine)
  • Verdiperstat (Biohaven)
  • Zilucoplan (Ra Pharmaceutical)

—Edaravone study participants must either not take edaravone or have completed at least one cycle of edaravone prior to the Master Protocol Screening Visit. Edaravone-naïve participants are permitted in the study

See reference

Ravulizumab (Alexion)

—Edaravone study participants must be on a stable dose for 60 days (2 cycles)

See reference

According to ClinicalTrials.gov, the following clinical trial mentions edaravone in the exclusion criteria:

CuATSM (Collaborative Medicinal Development Pty Limited)

—No prior exposure to agents other than riluzole for the treatment of ALS

See reference

There may be some clinical trials for ALS currently underway that do not mention the use of edaravone.

Please refer to each sponsor for complete and current information about each clinical trial, including protocols and inclusion/exclusion criteria.

Mitsubishi Tanabe Pharma America, Inc. ("MTPA") is not affiliated with the companies or products listed herein. This information is for general reference only and was sourced directly from ClinicalTrials.gov as of May 14, 2020. MTPA makes no representation to the accuracy, veracity, completeness or currentness of this information. Please refer to each company for complete and current information about each clinical trial, including protocols and inclusion/exclusion criteria.

This information does not constitute an endorsement, negative or positive comment or referral of any kind and is not intended as medical advice or a substitute for independent clinical assessment or judgment. Healthcare providers are solely responsible for independent verification of clinical trial protocol information, including trial inclusion/exclusion criteria. MTPA, as well as its employees or agents, shall not be held liable for any damages or harm resulting from any use or reliance on this information.

All company names, product names, trial names, trademarks, trade names or other registered marks are the property of their respective owners.

aMTPA is the manufacturer of edaravone in the United States and is not affiliated with the companies or products listed above. This information is for reference only and was sourced from ClinicalTrials.gov as of May 14, 2020. Please refer to each company’s website to confirm the current details of each clinical trial, including protocols and inclusion/exclusion criteria.

You are now leaving alstrials.com

You are leaving this website, hosted by Mitsubishi Tanabe Pharma America, Inc.


This link will take you to a website to which our Privacy Policy does not apply. Mitsubishi Tanabe Pharma America, Inc. does not control the content of this third-party site.

CONTINUE
CANCEL
CANCEL
CONTINUE